Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Validation of an algorithm for identifying MS cases in administrative health claims datasets.

Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG; United States Multiple Sclerosis Prevalence Workgroup (MSPWG).

Neurology. 2019 Feb 15. pii: 10.1212/WNL.0000000000007043. doi: 10.1212/WNL.0000000000007043. [Epub ahead of print]

PMID:
30770432
2.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Feb 15. pii: 10.1212/WNL.0000000000007035. doi: 10.1212/WNL.0000000000007035. [Epub ahead of print]

PMID:
30770430
3.

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG; United States Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Feb 15. pii: 10.1212/WNL.0000000000007044. doi: 10.1212/WNL.0000000000007044. [Epub ahead of print] Review.

PMID:
30770422
4.

Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.

Mexhitaj I, Nyirenda MH, Li R, O'Mahony J, Rezk A, Rozenberg A, Moore CS, Johnson T, Sadovnick D, Collins DL, Arnold DL, Gran B, Yeh EA, Marrie RA, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network .

Brain. 2019 Feb 12. doi: 10.1093/brain/awz017. [Epub ahead of print]

PMID:
30759186
5.

A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis.

Fadda G, Brown RA, Magliozzi R, Aubert-Broche B, O'Mahony J, Shinohara RT, Banwell B, Marrie RA, Yeh EA, Collins LD, Arnold DL, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

Ann Neurol. 2019 Feb 4. doi: 10.1002/ana.25429. [Epub ahead of print]

PMID:
30719730
6.

The prodrome in relapsing remitting and primary progressive multiple sclerosis.

Wijnands JMA, Zhu F, Kingwell E, Zhao Y, Evans C, Fisk JD, Marrie RA, Tremlett H.

Eur J Neurol. 2019 Feb 3. doi: 10.1111/ene.13925. [Epub ahead of print]

PMID:
30714270
7.

Accuracy of FRAX® in people with multiple sclerosis.

Bisson EJ, Finlayson ML, Ekuma O, Marrie RA, Leslie WD.

J Bone Miner Res. 2019 Jan 28. doi: 10.1002/jbmr.3682. [Epub ahead of print]

PMID:
30690793
8.

Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Mowry EM, Marrie RA.

Mult Scler Relat Disord. 2019 Jan 24;29:86-93. doi: 10.1016/j.msard.2019.01.031. [Epub ahead of print]

PMID:
30690340
9.

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.

Lancet Neurol. 2019 Feb;18(2):185-197. doi: 10.1016/S1474-4422(18)30460-5. Review.

PMID:
30663608
10.

Factors associated with receiving bone mineral density screening among people with multiple sclerosis.

Bisson EJ, Ekuma O, Marrie RA, Leslie WD, Finlayson ML.

Mult Scler Relat Disord. 2019 Jan 8;28:305-308. doi: 10.1016/j.msard.2019.01.022. [Epub ahead of print]

PMID:
30641355
11.

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006854. doi: 10.1212/WNL.0000000000006854. [Epub ahead of print]

PMID:
30635487
12.

MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis.

Wijnands JMA, Ekuma O, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H, Marrie RA.

Mult Scler Relat Disord. 2018 Dec 23;28:138-144. doi: 10.1016/j.msard.2018.12.030. [Epub ahead of print]

PMID:
30594814
13.

Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA.

Neurol Clin Pract. 2018 Dec;8(6):472-481. doi: 10.1212/CPJ.0000000000000523.

PMID:
30588376
14.

Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study.

Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Daeninck P, Bolton J, Sareen J, Leong C.

CMAJ Open. 2018 Dec 18;6(4):E637-E642. doi: 10.9778/cmajo.20180109. Print 2018 Oct-Dec.

15.

A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?

Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G.

Microbiome. 2018 Dec 13;6(1):221. doi: 10.1186/s40168-018-0603-4.

16.

Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.

Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, Evans C, Tremlett H.

Mult Scler Relat Disord. 2019 Jan;27:364-369. doi: 10.1016/j.msard.2018.11.004. Epub 2018 Nov 9.

PMID:
30476872
17.

Obesity and brain volume loss in multiple sclerosis.

Marrie RA, Butzkueven H, Ascherio A.

Neurology. 2018 Dec 11;91(24):1079-1080. doi: 10.1212/WNL.0000000000006638. Epub 2018 Nov 14. No abstract available.

PMID:
30429279
18.

Diabetes and anxiety adversely affect cognition in multiple sclerosis.

Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff L, Mazerolle EL, Marriott JJ, Bernstein CN, Fisk JD; Comorbidity and Cognition in Multiple Sclerosis (CCOMS) Study Group.

Mult Scler Relat Disord. 2019 Jan;27:164-170. doi: 10.1016/j.msard.2018.10.018. Epub 2018 Oct 23.

19.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
20.

Use of eHealth and mHealth technology by persons with multiple sclerosis.

Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A.

Mult Scler Relat Disord. 2019 Jan;27:13-19. doi: 10.1016/j.msard.2018.09.036. Epub 2018 Oct 2.

PMID:
30296732
21.

Incidence and prevalence of MS in children: A population-based study in Ontario, Canada.

Marrie RA, O'Mahony J, Maxwell C, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2018 Oct 23;91(17):e1579-e1590. doi: 10.1212/WNL.0000000000006395. Epub 2018 Sep 26.

PMID:
30258022
22.

Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.

Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA; CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease”.

Mult Scler Relat Disord. 2018 Nov;26:124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12. Review.

23.

Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes.

Longoni G, Brown RA, Aubert-Broche B, Grover SA, Branson HM, Fetco D, Bar-Or A, Marrie RA, Motl RW, Collins DL, Narayanan S, Arnold DL, Banwell B, Yeh EA.

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 6;5(6):e499. doi: 10.1212/NXI.0000000000000499. eCollection 2018 Nov.

24.

MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.

Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi: 10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.

PMID:
30169254
25.

Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.

O'Mahony J, Marrie RA, Laporte A, Bar-Or A, Yeh EA, Brown A, Dilenge ME, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676. [Epub ahead of print]

PMID:
30160208
26.

Identifying optic neuritis and transverse myelitis using administrative data.

Marrie RA, Ekuma O, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:258-264. doi: 10.1016/j.msard.2018.08.013. Epub 2018 Aug 13.

PMID:
30144696
27.

Mining healthcare data for markers of the multiple sclerosis prodrome.

Högg T, Wijnands JMA, Kingwell E, Zhu F, Lu X, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:232-240. doi: 10.1016/j.msard.2018.08.007. Epub 2018 Aug 8.

PMID:
30121490
28.

Identifying priority outcomes that influence selection of disease-modifying therapies in MS.

Day GS, Rae-Grant A, Armstrong MJ, Pringsheim T, Cofield SS, Marrie RA.

Neurol Clin Pract. 2018 Jun;8(3):179-185. doi: 10.1212/CPJ.0000000000000449.

PMID:
30105155
29.

Factors associated with perceived need for mental health care in multiple sclerosis.

Orr J, Bernstein CN, Graff LA, Patten SB, Bolton JM, Sareen J, Marriott JJ, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Mult Scler Relat Disord. 2018 Oct;25:179-185. doi: 10.1016/j.msard.2018.07.043. Epub 2018 Jul 29.

30.

Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.

Setayeshgar S, Kingwell E, Zhu F, Zhang X, Zhang T, Marrie RA, Carruthers R, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:57-60. doi: 10.1016/j.msard.2018.07.012. Epub 2018 Jul 9.

PMID:
30036855
31.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

PMID:
30013178
32.

Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease.

Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, Graff LA, Patten SB, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Inflamm Bowel Dis. 2019 Jan 10;25(2):360-368. doi: 10.1093/ibd/izy235.

PMID:
29986021
33.

Five years before multiple sclerosis onset: Phenotyping the prodrome.

Wijnands JM, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662. [Epub ahead of print]

PMID:
29979093
34.

Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases.

Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72. doi: 10.1016/j.genhosppsych.2018.06.001. Epub 2018 Jun 7.

35.

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

Mahmud SM, Bozat-Emre S, Mostaço-Guidolin LC, Marrie RA.

Emerg Infect Dis. 2018 Jul;24(7):1267-1274. doi: 10.3201/eid2407.161783.

36.

The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases.

Enns MW, Bernstein CN, Kroeker K, Graff L, Walker JR, Lix LM, Hitchon CA, El-Gabalawy R, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

PLoS One. 2018 Jun 7;13(6):e0198975. doi: 10.1371/journal.pone.0198975. eCollection 2018.

37.

Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.

Maranzano J, Till C, Assemlal HE, Fonov V, Brown R, Araujo D, O'Mahony J, Yeh EA, Bar-Or A, Marrie RA, Collins L, Banwell B, Arnold DL, Narayanan S; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952. [Epub ahead of print]

PMID:
29852831
38.

Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study.

McKay KA, Marrie RA, Fisk JD, Patten SB, Tremlett H.

Neuroepidemiology. 2018;51(1-2):1-10. doi: 10.1159/000488799. Epub 2018 May 15.

PMID:
29763935
39.

Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.

Marrie RA, Montalban X.

Mult Scler. 2018 Apr;24(5):558-562. doi: 10.1177/1352458518767323. No abstract available.

PMID:
29692224
40.

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):789-800. doi: 10.1212/WNL.0000000000005345.

PMID:
29686117
41.

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):777-788. doi: 10.1212/WNL.0000000000005347. Erratum in: Neurology. 2019 Jan 8;92(2):112.

PMID:
29686116
42.

Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2018 Mar-Apr;20(2):76-84. doi: 10.7224/1537-2073.2016-110.

43.

The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.

Bernstein CN, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott J, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy068. [Epub ahead of print]

PMID:
29668911
44.

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056. doi: 10.1136/jnnp-2017-317493. Epub 2018 Mar 30.

PMID:
29602795
45.

Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan.

Al-Sakran LH, Marrie RA, Blackburn DF, Knox KB, Evans CD.

Can J Neurol Sci. 2018 May;45(3):295-303. doi: 10.1017/cjn.2017.301. Epub 2018 Mar 20.

PMID:
29557321
46.

Temporal trends in multiple sclerosis prevalence and incidence in a large population.

Rotstein DL, Chen H, Wilton AS, Kwong JC, Marrie RA, Gozdyra P, Krysko KM, Kopp A, Copes R, Tu K.

Neurology. 2018 Apr 17;90(16):e1435-e1441. doi: 10.1212/WNL.0000000000005331. Epub 2018 Mar 16.

PMID:
29549225
47.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.

PMID:
29523642
48.

Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease.

Litster B, Bernstein CN, Graff LA, Walker JR, Fisk JD, Patten SB, Bolton JM, Sareen J, El-Gabalawy R, Marrie RA.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1641-1648. doi: 10.1093/ibd/izy032.

PMID:
29522100
49.

Lower prevalence of multiple sclerosis in First Nations Canadians.

Marrie RA, Leung S, Yu N, Elliott L.

Neurol Clin Pract. 2018 Feb;8(1):33-39. doi: 10.1212/CPJ.0000000000000418. Review.

50.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324

Supplemental Content

Loading ...
Support Center